Resources
Did you mean
AstraZeneca Plc. (17 results)
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- GM Signals It's Getting Out of the Volume Game
- An ancient auto industry joke, probably dating back to the dawn of industrial time, has it that a car company "loses money on every car, but makes it up on volume." The joke is, that's impossible. Obviously, if you lose money on every car, the more you sell, the more...
- Blog posts 2008-04-18
Additional Resources
- First in the Queue
- Wimbledon Diary Sleeping on the pavement is part of the whole Wimbledon experience. Each day we'll bring you an interview with the first person in the queue for the day's play. Name Mark Oakley. From: Totton, Hampshire. Age:...
- Articles 2008-06-26
- A Competitor Analysis of the Antihypertensives Market Including Detailed Market Information and Major Companies Active in the Industry
- DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/1d8ee0/competitor_analysi) has announced the addition of the "Competitor Analysis: Antihypertensives" report to their offering. The Competitive Intelligence Report Antihypertensives as of June 2008 provides a competitor analysis in the development pipeline of novel treatments of pulmonary artery hypertension, arterial hypertension, portal hypertension...
- Articles 2008-06-25
- Eaton holds aces to hit unlikely heights
- Chris Eaton left his parents' home in his patched up Vauxhall Astra yesterday morning, strung his own tennis racket and prepared for his seventh match of his year's Wimbledon; one which no one gave him - a player ranked 661st in the world - the faintest hope of winning. ...
- Articles 2008-06-25
- DIREVO Receives Broad European Patent Protection for its Protease Optimization Platform
- DIREVO Biotech AG, a world-wide leader inhigh throughput protein and strain engineering, announced today receipt ofnotice from the European Patent Office that the post-granting oppositionperiod had ended without a filed opposition against Patent Grant No. EP150411. This patent, entitled, "Process for Generating Sequence-SpecificProteases by Directed Evolution", broadly claims methods for...
- Articles 2008-06-24
- Zacks Bull and Bear of the Day Highlights: Vivo Participacoes, Werner Enterprises, AstraZeneca, Raytheon and Primedia
- CHICAGO -- Zacks Equity Research highlights Vivo Participa[?][?]es (NYSE: VIV) as the Bull of the Day and Werner Enterprises, Inc. (Nasdaq: WERN) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on AstraZeneca (NYSE: AZN), Raytheon Company (NYSE: RTN) and Primedia, Inc. (NYSE: PRM). ...
- Articles 2008-06-24
- New Pharmaxis Board Appointment
- SYDNEY, Australia, June 23 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis today announced the appointment of senior Australian pharmaceutical executive Will Delaat to its board of directors. Mr Delaat has 35 years experience in the global pharmaceutical industry, most recently as the managing director of the Australian subsidiary of Merck &...
- Articles 2008-06-24
- Astra may be pricey, but you get what you pay for
- What a great time for General Motors to have a sweet-driving, decent-looking small car like the Saturn Astra. It's a barely Americanized German Opel Astra and went on sale in the USA in January. Saturn and Opel are both General Motors brands, and it cuts costs for GM...
- Articles 2008-06-20
- Main movers
- Go-Ahead 1,707p (up 184p, 12.08 per cent) Pre-close update pleases. Eurasian Natural Resources Corporation 1,514p (up 49p, 3.34 per cent) Sector strength; positive comment from Morgan Stanley. Pennon 636.5p (up 13p, 2.09 per cent) Upgraded to "overweight" from "equal-weight" at Morgan Stanley. ...
- Articles 2008-06-20
- Weitz & Luxenberg Files Seroquel Diabetes Lawsuit Against AstraZeneca
- AstraZeneca's CEO to be Deposed in London on Friday, June 20, 2008 NEW YORK, June 19 /PRNewswire/ -- Weitz & Luxenberg, PC, one of the leading plaintiffs' litigation law firms in America, filed a lawsuit today against pharmaceutical giant AstraZeneca on behalf of a New York City...
- Articles 2008-06-19
- Zacks Analyst Interview Highlights: Syngenta, Novartis, AstraZeneca and Monsanto
- CHICAGO -- Zacks.com releases the latest Analyst Interview. Today's interview is with senior analyst Santiago Burgaleta, who discusses Syngenta (NYSE: SYT), Novartis AG (NYSE: NVS), AstraZeneca PLC (NYSE: AZN) and Monsanto (NYSE: MON). A synopsis of today's Analyst Interview is presented below. The full article can be read...
- Articles 2008-06-18
- Verus Pharmaceuticals Announces Divestiture of Pediatric GI Development Program to Meritage Pharma
- Spin-out of Program Allows Verus to Focus Solely on AstraZeneca Collaboration SAN DIEGO, June 16 /PRNewswire/ -- Verus Pharmaceuticals, Inc., a pediatric-oriented specialty pharmaceutical company, announced today that Meritage Pharma, Inc., a newly formed specialty pharmaceutical company, has acquired its pediatric gastrointestinal development program. Included in...
- Articles 2008-06-16
- Medicare Decision Improves Quality of Life, Gives ALL Patients Access to "Single Use" Catheters
- Leading catheter Astra Tech's LoFric([R]) now an option for those on Medicare and Medicaid TORRANCE, Calif. -- A sweeping change in the Centers for Medicare and Medicaid Services CMS policy now allows patients on intermittent catheterization up to 200 single-use, disposable catheters per month, including the industry-leading LoFric,...
- Articles 2008-06-16
- Swedish IT company Sigma AB receives contract expansion from AstraZeneca
- NORDIC BUSINESS REPORT-12 June 2008-Swedish IT company Sigma AB receives contract expansion from AstraZenecaC1994-2008 M2 COMMUNICATIONS LTD http://www.m2.com Swedish IT company Sigma AB (OMX Stockholm:SIGM B) said on Thursday (11 June) that it has received a contract expansion from the Anglo-Swedish pharmaceutical group AstraZeneca (LSE:AZN) (NYSE:AZN) (OMX Stockholm:AZN)....
- Articles 2008-06-12
- Cellectricon and AstraZeneca - Partners in New High Throughput Ion Channel Drug Discovery Technology
- GOTHENBURG, Sweden, June 11 /PRNewswire/ -- Cellectricon, a leading provider of screening solutions for drug discovery, today announced a new collaborative agreement with AstraZeneca. Under the agreement Cellectricon will provide AstraZeneca with two of its new groundbreaking high throughput platform, DynaflowRHT, for ion channel screening. Cellectricon and...
- Articles 2008-06-11
- Targacept and AstraZeneca Initiate Clinical Trial of AZD3480 in Adult ADHD
- WINSTON-SALEM, N.C. -- Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics TM, today announced the initiation of a Phase 2 clinical trial of AZD3480 (TC-1734) in adults with Attention Deficit/Hyperactivity Disorder, or ADHD. "In our previous clinical trials...
- Articles 2008-06-10
- WuXi PharmaTech Expands Collaboration With AstraZeneca
- SHANGHAI, China, June 10 /Xinhua-PRNewswire/ -- WuXi PharmaTech , a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that it has signed a new three-year collaboration agreement with AstraZeneca. (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ) In...
- Articles 2008-06-10
- Mylan Wins Generic Prilosec® Patent Litigation
- Court of Appeals Affirms No Infringement PITTSBURGH, June 10 /PRNewswire-FirstCall/ -- Mylan Inc. announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed a May 2007 District Court ruling stating that Mylan's 10 mg and 20 mg Omeprazole delayed-release capsules do not...
- Articles 2008-06-10
- Senior Pharmaceutical Executive, Glenn J. Gormley, M.D., Ph.D., to Lead Gemin X Pharmaceuticals as President and CEO
- MALVERN, Pa. & MONTREAL -- Gemin X Pharmaceuticals, a privately held pharmaceutical company focused on developing novel treatments for cancer, is pleased to announce the appointment of Dr. Glenn J. Gormley as President and Chief Executive Officer of the Company. Dr. Gormley has held senior executive positions at Novartis, AstraZeneca...
- Articles 2008-06-10
- ONGLYZA™ Demonstrated Significant Reductions in Key Measures of Glucose Control in Treatment Naive People with Type 2 Diabetes
- SAN FRANCISCO -- Results from a 24-week Phase III study presented at the 68th American Diabetes Association Annual Scientific Sessions demonstrated that saxagliptin, a selective, reversible inhibitor of the dipeptidyl peptidase (DPP-4) enzyme in development by Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN), produced significant reductions in key...
- Articles 2008-06-07
- << Previous
- page 1 of 1
- Next >>
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
- Dell: Built to fit your business needs.
-
Powerful, Dell is built to fit your business needs Customized systems, experts trained in small business, 24/7/365 support, and powerful, reliable technology. Dell, big results for small business.
- Learn More >>
- Create new ways to live, work and play with Intel
-
Learn how Intel researchers around the world are developing with tera-scale computing, wireless computing anywhere on earth, advanced exploratory research, and more.
- Learn about new technology that improves every facet of life >>
- Revolutionary Manufacturing
-
Get inside Intel's advanced manufacturing processes, including research and development, wafer fabrication, and boards and semi-conductor manufacturing.
- Read how Intel is precision tuning fast, smart, more energy-efficient technologies >>
